Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
Persons over 18 years of age and under 65 years of age.
Schizophrenia or bipolar affective disorder established by the usual diagnostic criteria applied in a psychiatric clinic or hospital ward/unit within the clinic or outpatient.
Patients who are treated as outpatients, inpatients or have been discharged from the clinic/hospital with a recommendation for quetiapine monotherapy or combination therapy of quetiapine with aripiprazole or haloperidol. Recommended by a specialist psychiatrist/neuropsychiatrist in clinical and hospital centers and through specialist-consultant outpatient clinics in Bosnia and Herzegovina.
You may not be if
Persons younger than 18 years and older than 65 years
Hypersensitivity to the components of the drug
Positive history of angioneurotic edema
Pregnancy
Breastfeeding
Simultaneous use with cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone
Patients who are planning to become pregnant in the near future
Diagnosed medical conditions that may constitute a contraindication for the use of the drug quetiapine
Withdrawal Criteria:
Deterioration of the underlying disease that requires therapy discontinuation
Development of serious adverse events requiring therapy discontinuation
Occurence of pregnancy
Development of another disease that affects the course of the study
Clareo Health | Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
